Literature DB >> 17566740

Antibodies to HIV-1: aiming at the right target.

Dirk Eggink1, Mark Melchers, Rogier W Sanders.   

Abstract

HIV-1 evades antibody-mediated neutralization in many cunning ways. The recent structural characterization of a conserved neutralization epitope on the envelope glycoprotein complex (Env) provides clues to the vulnerabilities of the virus. We discuss these observations and explain their relevance for HIV-1 vaccine design.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17566740     DOI： 10.1016/j.tim.2007.05.006

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  8 in total

1.  Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution.

Authors:  Ilja Bontjer; Mark Melchers; Dirk Eggink; Kathryn David; John P Moore; Ben Berkhout; Rogier W Sanders
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

2.  Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.

Authors:  Antu K Dey; Kathryn B David; Min Lu; John P Moore
Journal:  Virology       Date:  2009-01-08       Impact factor: 3.616

3.  Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Authors:  Mark Melchers; Ilja Bontjer; Tommy Tong; Nancy P Y Chung; Per Johan Klasse; Dirk Eggink; David C Montefiori; Maurizio Gentile; Andrea Cerutti; William C Olson; Ben Berkhout; James M Binley; John P Moore; Rogier W Sanders
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

4.  A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.

Authors:  Mark Melchers; Katie Matthews; Robert P de Vries; Dirk Eggink; Thijs van Montfort; Ilja Bontjer; Carolien van de Sandt; Kathryn David; Ben Berkhout; John P Moore; Rogier W Sanders
Journal:  Retrovirology       Date:  2011-06-20       Impact factor: 4.602

Review 5.  Plant made anti-HIV microbicides--a field of opportunity.

Authors:  Hester C T Lotter-Stark; Edward P Rybicki; Rachel K Chikwamba
Journal:  Biotechnol Adv       Date:  2012-06-28       Impact factor: 14.227

6.  Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects.

Authors:  Filippo Canducci; Maria Chiara Marinozzi; Michela Sampaolo; Stefano Berrè; Patrizia Bagnarelli; Massimo Degano; Giulia Gallotta; Benedetta Mazzi; Philippe Lemey; Roberto Burioni; Massimo Clementi
Journal:  Retrovirology       Date:  2009-01-15       Impact factor: 4.602

7.  Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.

Authors:  Marcos Pérez-Losada; David Posada; Miguel Arenas; David V Jobes; Faruk Sinangil; Phillip W Berman; Keith A Crandall
Journal:  Retrovirology       Date:  2009-07-15       Impact factor: 4.602

8.  The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion.

Authors:  Rogier W Sanders; Eelco van Anken; Alexei A Nabatov; I Marije Liscaljet; Ilja Bontjer; Dirk Eggink; Mark Melchers; Els Busser; Martijn M Dankers; Fedde Groot; Ineke Braakman; Ben Berkhout; William A Paxton
Journal:  Retrovirology       Date:  2008-01-31       Impact factor: 4.602
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.